Consensus recommendations for measuring the impact of contraception on the menstrual cycle in contraceptive clinical trials
Author:
Mackenzie Amelia C. L.ORCID, Chung StephanieORCID, Hoppes EmilyORCID, Miller Nora, Burke Anne E.ORCID, Achilles Sharon L.ORCID, Allen C. LeighORCID, Bahamondes LuisORCID, Blithe Diana L.ORCID, Brache VivianORCID, Callahan Rebecca L., Cartwright Alice F.ORCID, Clancy Kathryn B. H.ORCID, Colli Enrico, Cordova-Gomez AmandaORCID, Costenbader Elizabeth E.ORCID, Creinin Mitchell D.ORCID, Critchley Hilary O. D.ORCID, Doncel Gustavo F., Dorflinger Laneta J., Edelman Alison, Faustmann Thomas, Gerlinger ChristophORCID, Haddad Lisa B., Hennegan JulieORCID, Juliato Cássia Raquel TeatinORCID, Kibira Simon P. S.ORCID, Mansour Diana, Martinez AndresORCID, Matteson Kristen A., Maybin Jacqueline A.ORCID, Mickler Alexandria K.ORCID, Nanda Kavita, Nwachukwu Chukwuemeka E.ORCID, OlaOlorun Funmilola M.ORCID, Peine Kevin J., Polis Chelsea B.ORCID, Vieira Carolina SalesORCID, Sitruk-Ware RegineORCID, Smit Jennifer A.ORCID, Solomon Marsden, Soule Lisa M., Taylor Douglas, Tolley Elizabeth E.ORCID, Vandeputte Olivia
Abstract
AbstractObjectiveWe sought to develop consensus recommendations for improved measurement of contraceptive-induced menstrual changes (CIMCs) in contraceptive clinical trials to build upon previous standardization efforts.Study DesignWe undertook a virtual consensus-building process using a modified Delphi approach, incorporating aspects of Nominal Group Technique and the Jandhyala method. The process consisted of four half-day meetings, developing recommendations within five topical working groups, a series of consensus questionnaires to assess recommendation agreement on a 4-point Likert-like scale, and opportunities for input and feedback throughout the process. Recommendations required at least 75% consensus to be included.ResultsOur interdisciplinary group—from 26 organizations and 13 countries in five global regions across academia, nonprofit research organizations, the pharmaceutical industry, and funding agencies— developed 44 consensus recommendations. These included recommendations on standardization, patient-reported outcome measure development aligned with current regulatory guidance, trial design, protocol development, participant recruitment, data collection, data analysis, and areas for exploratory research. Seven recommendations were deemed a priority by over 85% of our group.ConclusionUsing a formal consensus-building process, we reached high levels of agreement around recommendations for more standardized and patient-centered measurement of CIMCs in contraceptive clinical trials, now and in the future.Implications statementConsensus recommendations on measuring bleeding changes and related outcomes in contraceptive clinical trials can improve reporting of standardized, patient-centered outcomes in future product labeling. These improvements can enable providers to offer more relevant counseling on contraceptives and permit greater comparability and data synthesis across trials to inform clinical guidance.
Publisher
Cold Spring Harbor Laboratory
|
|